Full Title: LIGHTBEAM-U01 Substudy 01A: A Phase 1/2 Substudy to Evaluate the Safety and Efficacy of Zilovertamab Vedotin in Pediatric and Young Adult Participants With Hematologic Malignancies or Solid Tumors
Status: Active, Recruiting
Age Range: 0.5 - 25 years old
Locations:
- Royal Victoria Infirmary- Great North Children's Hospital, Newcastle upon Tyne
- University College London Hospital, London
- University Hospital Wales, Cardiff
Registry Number: NCT06395103
Substudy 01A is part of a platform study. The purpose of this study is to assess the efficacy and safety of zilovertamab vedotin in pediatric participants with relapsed or refractory B-cell acute lymphoblastic leukemia (B-ALL), diffuse large B-cell lymphoma (DLBCL)/Burkitt lymphoma, or neuroblastoma and in pediatric and young adult participants with Ewing sarcoma.
If you would like any more information on clinical trials in general, please contact us at The Bone Cancer Research Trust.
Donate now (This link opens in a new window) More about Ewing sarcoma